Pfizer Inc. (NYSE:PFE) has been given a $36.00 price target by investment analysts at Sanford C. Bernstein in a report issued on Wednesday. The firm presently has a a “buy” rating on the biopharmaceutical company’s stock. Sanford C. Bernstein’s price objective indicates a potential upside of 10.13% from the stock’s previous close.

Several other equities analysts also recently commented on the company. BMO Capital Markets reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of Pfizer in a research report on Tuesday. Vetr raised Pfizer from a “buy” rating to a “strong-buy” rating and set a $37.42 price objective on the stock in a research report on Monday. Jefferies Group downgraded Pfizer from a “buy” rating to a “hold” rating and cut their price objective for the company from $39.00 to $36.00 in a research report on Thursday, October 13th. Argus reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a research report on Tuesday, October 4th. Finally, Bank of America Corp. reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Pfizer in a research report on Tuesday, September 27th. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $38.55.

Analyst Recommendations for Pfizer (NYSE:PFE)

Shares of Pfizer (NYSE:PFE) traded down 0.2065% during trading on Wednesday, reaching $32.6225. The company’s stock had a trading volume of 1,306,757 shares. The company has a 50-day moving average price of $33.89 and a 200-day moving average price of $34.37. The stock has a market cap of $197.88 billion, a price-to-earnings ratio of 28.9207 and a beta of 0.86. Pfizer has a one year low of $28.25 and a one year high of $37.39.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a return on equity of 23.37% and a net margin of 14.88%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the prior year, the firm posted $0.56 EPS. Pfizer’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Pfizer will post $2.46 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s payout ratio is currently 95.24%.

A number of hedge funds have recently modified their holdings of PFE. Ronna Sue Cohen raised its stake in shares of Pfizer by 0.4% in the second quarter. Ronna Sue Cohen now owns 7,881 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 35 shares during the last quarter. Forte Capital LLC ADV raised its stake in shares of Pfizer by 0.4% in the first quarter. Forte Capital LLC ADV now owns 8,589 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 36 shares in the last quarter. Delphi Private Advisors LLC raised its stake in shares of Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 47 shares in the last quarter. Acadia Trust NA raised its stake in shares of Pfizer by 0.5% in the second quarter. Acadia Trust NA now owns 14,032 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 67 shares in the last quarter. Finally, New England Private Wealth Advisors LLC raised its stake in shares of Pfizer by 0.4% in the second quarter. New England Private Wealth Advisors LLC now owns 18,135 shares of the biopharmaceutical company’s stock worth $639,000 after buying an additional 77 shares in the last quarter. 69.66% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

5 Day Chart for NYSE:PFE

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.